<p>, /PRNewswire/ -- Pomerantz LLP 宣布已对 Aldeyra Therapeutics, Inc.（&#34;Aldeyra&#34; 或 &#34;公司&#34;）（NASDAQ: ALDX）提起集体诉讼。建议相关投资者联系 Danielle Peyton，邮箱为 [email protected] 或拨打 646-581-9980（或 888.4-POMLAW），免费电话，分机 7980。通过电子邮件咨询的投资者被鼓励提供他们的邮寄地址、电话号码和购买的股票数量。</p>
<p>该集体诉讼涉及 Aldeyra 及其某些高管和/或董事是否参与了证券欺诈或其他非法商业行为。</p>
<p><strong>如果您在集体诉讼期间购买或以其他方式获得了</strong> <strong>Aldeyra</strong> <strong>证券，您有直到 2026 年 5 月 29 日的时间请求法院任命您为首席原告。投诉的副本可以在</strong> <strong>www.pomerantzlaw.com</strong> <strong>获取。</strong></p>
<p><strong>[点击这里获取有关加入集体诉讼的信息]</strong></p>
<p>2026 年 3 月 17 日，Aldeyra 发布了一份新闻稿，&#34;宣布收到美国食品药品监督管理局（FDA）对 reproxalap 的新药申请（NDA）的完整回应信（CRL），该药物为治疗干眼症的研究药物候选。&#34; 根据 Aldeyra 的新闻稿，&#34;CRL 表示，存在'缺乏足够且经过良好控制的研究的实质性证据……该药物在其建议的标签下的使用条件下将具有其所声称或表示的效果'，并且'申请未能在治疗干眼症的体征和症状方面的充分且经过良好控制的研究中证明疗效。' 信中还指出，'研究结果的不一致性对积极发现的可靠性和意义提出了严重担忧'，并且'已完成临床试验的证据总和不支持该产品的有效性。'&#34;</p>
<p>在这一消息发布后，Aldeyra 的股价下跌了 2.99 美元，或 70.69%，在 2026 年 3 月 17 日收于每股 1.24 美元。</p>
<p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为公司、证券和反垄断集体诉讼领域的顶尖律师事务所之一。该事务所由已故的 Abraham L. Pomerantz 创立，他被称为集体诉讼领域的开创者，Pomerantz 在证券集体诉讼领域开创了先河。今天，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、信托责任违反和公司不当行为的受害者争取权利。该事务所已为集体成员追回了众多数百万美元的赔偿金。请访问 www.pomlaw.com。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p><strong>联系方式：</strong></p>
<p>Danielle Peyton</p>
<p>Pomerantz LLP</p>
<p>[email protected]</p>
<p>646-581-9980 分机 7980</p>
<p>来源 Pomerantz LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTIxJk5ld3NJdGVtSWQ9REM2NTU5NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjExNTEwUFJfTkVXU19VU1BSX19fX19EQzY1NTk1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTIxJk5ld3NJdGVtSWQ9REM2NTU5NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjExNTEwUFJfTkVXU19VU1BSX19fX19EQzY1NTk1"/></p>

Aldeyra治疗

<p>Pomerantz 律师事务所已对 Aldeyra Therapeutics, Inc.（NASDAQ: ALDX）提起集体诉讼，指控其涉嫌证券欺诈。遭受损失的投资者被鼓励在 2026 年 5 月 29 日之前联系该事务所，以被任命为首席原告。该诉讼是在 Aldeyra 因其针对干眼症的研究药物收到 FDA 的完整回应信后，股价大幅下跌的背景下提起的，信中指出其疗效证据不足</p>

<p>, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (&#34;Aldeyra&#34; or the &#34;Company&#34;) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Pomerantz LLP 宣布已对 Aldeyra Therapeutics, Inc.（&#34;Aldeyra&#34; 或 &#34;公司&#34;）（NASDAQ: ALDX）提起集体诉讼。建议相关投资者联系 Danielle Peyton，邮箱为 [email protected] 或拨打 646-581-9980（或 888.4-POMLAW），免费电话，分机 7980。通过电子邮件咨询的投资者被鼓励提供他们的邮寄地址、电话号码和购买的股票数量。</p>
</div><p>The class action concerns whether Aldeyra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.</p>
<div class="lb-trans"><p>该集体诉讼涉及 Aldeyra 及其某些高管和/或董事是否参与了证券欺诈或其他非法商业行为。</p>
</div><p><strong>You have until May 29, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired</strong> <strong>Aldeyra</strong> <strong>securities during the Class Period. A copy of the Complaint can be obtained at</strong> <strong>www.pomerantzlaw.com</strong> <strong>.</strong></p>
<div class="lb-trans"><p><strong>如果您在集体诉讼期间购买或以其他方式获得了</strong> <strong>Aldeyra</strong> <strong>证券，您有直到 2026 年 5 月 29 日的时间请求法院任命您为首席原告。投诉的副本可以在</strong> <strong>www.pomerantzlaw.com</strong> <strong>获取。</strong></p>
</div><p><strong>[Click here for information about joining the class action]</strong></p>
<div class="lb-trans"><p><strong>[点击这里获取有关加入集体诉讼的信息]</strong></p>
</div><p>On March 17, 2026, Aldeyra issued a press release &#34;announc[ing] receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.&#34; According to Aldeyra's press release, &#34;[t] he CRL stated that there is 'a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling' and that 'the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.' The letter also stated that the 'inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings' and that the 'totality of evidence from the completed clinical trials does not support the effectiveness of the product.'&#34;</p>
<div class="lb-trans"><p>2026 年 3 月 17 日，Aldeyra 发布了一份新闻稿，&#34;宣布收到美国食品药品监督管理局（FDA）对 reproxalap 的新药申请（NDA）的完整回应信（CRL），该药物为治疗干眼症的研究药物候选。&#34; 根据 Aldeyra 的新闻稿，&#34;CRL 表示，存在'缺乏足够且经过良好控制的研究的实质性证据……该药物在其建议的标签下的使用条件下将具有其所声称或表示的效果'，并且'申请未能在治疗干眼症的体征和症状方面的充分且经过良好控制的研究中证明疗效。' 信中还指出，'研究结果的不一致性对积极发现的可靠性和意义提出了严重担忧'，并且'已完成临床试验的证据总和不支持该产品的有效性。'&#34;</p>
</div><p>On this news, Aldeyra's stock price fell $2.99 per share, or 70.69%, to close at $1.24 per share on March 17, 2026.</p>
<div class="lb-trans"><p>在这一消息发布后，Aldeyra 的股价下跌了 2.99 美元，或 70.69%，在 2026 年 3 月 17 日收于每股 1.24 美元。</p>
</div><p>Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.</p>
<div class="lb-trans"><p>Pomerantz LLP 在纽约、芝加哥、洛杉矶、伦敦、巴黎和特拉维夫设有办事处，被公认为公司、证券和反垄断集体诉讼领域的顶尖律师事务所之一。该事务所由已故的 Abraham L. Pomerantz 创立，他被称为集体诉讼领域的开创者，Pomerantz 在证券集体诉讼领域开创了先河。今天，85 年后，Pomerantz 继续秉承他所建立的传统，为证券欺诈、信托责任违反和公司不当行为的受害者争取权利。该事务所已为集体成员追回了众多数百万美元的赔偿金。请访问 www.pomlaw.com。</p>
</div><p>Attorney advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Danielle Peyton</p>
<div class="lb-trans"><p>Danielle Peyton</p>
</div><p>Pomerantz LLP</p>
<div class="lb-trans"><p>Pomerantz LLP</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>646-581-9980 ext. 7980</p>
<div class="lb-trans"><p>646-581-9980 分机 7980</p>
</div><p>SOURCE Pomerantz LLP</p>
<div class="lb-trans"><p>来源 Pomerantz LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTIxJk5ld3NJdGVtSWQ9REM2NTU5NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjExNTEwUFJfTkVXU19VU1BSX19fX19EQzY1NTk1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC65595&amp;Transmission_Id=202605211510PR_NEWS_USPR_____DC65595&amp;DateId=20260521"/></p>

15:10 ETINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX

15:10 ET 投资者警报：Pomerantz 律师事务所提醒在 Aldeyra 治疗公司投资中遭受损失的投资者注意集体诉讼及即将到来的截止日期 - ALDX